What TachoSil Treats: Main Uses and Benefits

TachoSil is applied across therapeutic domains where short-term symptomatic assistance is needed to manage physical manifestations during major surgery. It is commonly used as a supportive treatment in conditions characterized by periods of heightened symptoms, particularly when standard techniques may be insufficient for achieving internal stability.

It is primarily used to address diffuse oozing hemorrhage on organ surfaces like the liver and kidney, to manage localized bleeding at vascular suture lines, and to mitigate the risk of postoperative fluid and gas leakage in neurosurgery and thoracic procedures. This is relevant when groups of symptoms interfere with functional stability, such as persistent bleeding across a wide surgical field.

“TachoSil is commonly used when supportive symptom management is appropriate to achieve local control of blood loss and assist with tissue sealing.”

The overall therapeutic benefit provides support that helps ease the overall symptom burden associated with the clinical situation, such as leakage during recovery.

---

Quick Fact: Relief for Oozing Bleeding and Leakage Risk TachoSil supports hemostasis and sealing in surgical procedures involving the liver, kidney, lungs, major blood vessels, and the dura mater, contributing to easing the symptom load in acute clinical settings.

Regulatory References

1. European Medicines Agency (EMA) overview

Who Can and Cannot Use TachoSil?

The population eligibility for TachoSil is defined by governmental regulatory documents, focusing primarily on absolute contraindications and use restrictions related to age and administration.

Absolute Non-Eligibility (Contraindications)

TachoSil is contraindicated and must not be used in patients with a known hypersensitivity or allergy to its active components (human fibrinogen, human thrombin) or the excipient, equine collagen. Furthermore, the product must not be applied intravascularly (inside a blood vessel) under any circumstance, as this route of administration carries the risk of life-threatening blood clots.

Age- and Condition-Based Restrictions

Classification	Eligibility Status
Infants	Prohibited for use in infants under one month of age.
Pediatric Patients	Allowed for use in children from one month of age; however, older regulatory guidance stated it was not recommended for those under 18 years due to limited data.
Pregnant or Lactating Women	Safety is not established; use is restricted to when it is clearly needed.
Organ Impairment	No specific population restrictions are documented for patients with hepatic or renal impairment.

The regulatory labels also state that TachoSil is not established for use in treating major arterial or venous bleeding or for procedures in the renal pelvis.

Interactions with other medicines and products

The official regulatory profile for TachoSil is characterized by the local, topical use of the product, resulting in a distinct absence of documentation for systemic drug interactions.

Absence of Systemic Interactions

Interaction Type	Official Regulatory Statement
Systemic Drug-Drug	Regulatory documentation explicitly confirms that no formal interaction studies have been performed to evaluate the product’s effects on the pharmacokinetics or pharmacodynamics of co-administered systemic medicinal products.
Metabolic (CYP, Transporter)	Owing to its design as a topical fibrin sealant, and the minimal to negligible systemic absorption of its active components, TachoSil is not anticipated to participate in systemic enzyme-mediated or transporter-mediated interactions, and none are documented.

---

Documented Local Constraint

The only interaction detailed in official prescribing information is a mandatory local, physical constraint related to the surgical field preparation. The biological proteins (human fibrinogen and thrombin) are susceptible to denaturation upon contact with specific chemical substances.

Interacting Substance Category	Interaction Constraint and Timing Rule
Solutions containing Alcohol, Iodine, or Heavy Metals	These substances (often found in antiseptic solutions) may cause denaturation. Therefore, such solutions must be removed to the greatest possible extent from the application site immediately prior to applying the sealant patch.

This mandatory timing rule establishes a pre-administration restriction to maintain the activity of the fibrin sealant components. The label does not document any systemic interactions with ingested food, systemic alcohol, or herbal products.

How TachoSil Works

The function of TachoSil is one of rapid, localized biological seal formation, directly targeting the final molecular steps of the body’s clotting system.

---

Mechanism of Local Coagulation Cascade Bypass

This mechanism initiates the clotting process via direct enzymatic activation. The patch is coated with two primary biological targets: Human Thrombin (the enzyme) and Human Fibrinogen (the substrate). Upon application, the thrombin instantly acts as a serine protease, cleaving fibrinogen. This action completely bypasses the intrinsic and extrinsic coagulation pathways, contributing to the rapid initiation of the final common pathway.

---

Molecular Polymerization and Physical Sealing

The enzymatic cleavage results in fibrin monomers that spontaneously self-assemble through molecular polymerization, forming a dense, three-dimensional fibrin mesh that firmly adheres to the tissue surface. The resulting physiological effect is rapid adjunctive hemostasis and tissue sealing achieved by forming a dense mechanical obstruction at the application site.

---

Synergistic Delivery and Mechanical Constraint

This action is optimized by the collagen carrier, which ensures the simultaneous delivery and high local concentration of the enzyme and substrate, contributing to the stability and maximized speed of fibrin formation. However, this strictly localized mechanism is physically constrained and can be overridden by high-pressure, rapid blood flow which may prevent stable polymerization and adhesion.

How TachoSil is Used: Official Administration Guidelines

TachoSil is a ready-to-use drug-coated collagen patch intended strictly for topical use as an adjunct in surgery. Its administration is defined by its intra-operative role. It is not administered intravenously, orally, or in any other systemic manner.

---

Administration Scope

Entity	Official Administration Guideline
Route of administration	Topical use only, applied directly to the tissue surface.
Dosing schedule	Use is size-dependent; the smallest number and size of patches required to fully cover the bleeding or sealing area must be selected.
Frequency and duration	A single application is used once during a surgical procedure; the patch is designed to be left in place.
Age-group rules	No systemic dose adjustments are provided. Recommendations for pediatric use vary by regional clinical guidelines; some indicate use from one month of age, while others do not recommend use in children under 18 years due to insufficient data.

---

Procedural Administration Requirements

The correct application of TachoSil depends on specific steps outlined in the prescribing information.

1. Preparation: The application site must be cleansed and dried thoroughly to remove all fluids and disinfectants before the patch is applied.
2. Application: The patch is applied with the yellow, active side facing the tissue. If the surface is dry, the patch may be pre-moistened with 0.9% saline to aid adherence.
3. Adherence: The patch must be held in place with gentle pressure for at least three to five minutes to ensure it bonds firmly to the tissue.

These instructions describe the approach used for precise local control during surgery.

Research Evidence / Overview of Studies for TachoSil

## Evidence for Adjunctive Hemostasis in Liver Surgery

Research for the patch in liver surgery primarily involved controlled clinical trials as the main study design. These studies were designed to explore the evaluation of the patch against standard hemostatic techniques in adults undergoing elective liver resection (surgical removal of part of the liver).

The main outcome measured was the time required to achieve hemostasis (stopping the bleeding), tracked in minutes during the operation. Evidence describes the short-term patterns of bleeding control in this setting. However, the available data mainly relates to planned procedures, and research provides limited insight into performance during high-risk or emergency hepatic surgery.

## Evidence for Hemostasis and Sealing in Other Surgical Fields

The research scope includes other surgical areas, for which specific clinical trials and systematic reviews exist:

• Renal and Vascular Surgery: Research examined outcomes related to the time needed to control localized bleeding at the surgical site. Studies explored the patch's evaluation for hemostasis (bleeding control) at suture lines on major vessels and the heart.
• Thoracic and Neurological Surgery: Controlled trials were used to examine the patch's use for sealing air leaks from the lung surface and as an adjunct for sealing the dura mater (the brain and spinal cord membrane). Outcomes studied included the duration of air leakage and the occurrence of Cerebrospinal Fluid (CSF) leakage after surgery.

## Long-Term Studies and Follow-Up Data

The main clinical trials were primarily designed to track acute outcomes. Consequently, follow-up durations were limited in most pivotal efficacy research. Long-term effects are not fully established. A few observational studies, some monitoring patients over a period of many years, have described that remnants of the collagen carrier material can persist in some individuals.

## Evidence in Special Populations

The evidence base primarily focuses on adults undergoing elective surgery. The patch has been evaluated in a limited number of children undergoing specific procedures. The research volume in children is limited, and regulatory documentation notes that the available evidence for this population is still being developed.

Common questions about Tachosil (FAQ)

---

Q: Is Tachosil a type of glue or a drug?

A: TachoSil is officially regulated as a medicinal product or a drug-device combination product, rather than a conventional adhesive. It is categorized as a fibrin sealant patch or sealant matrix. It functions as a sealant matrix by utilizing the body's natural clotting factors to form a localized fibrin seal, which is its primary mechanism of action.

---

Q: Is Tachosil something that stays in the body permanently?

A: No, the patch is designed to be absorbable. The active clotting factors and the resulting fibrin are metabolized by the body over time. The collagen matrix that carries the factors is designed to biodegrade, indicating it is intended to be broken down and absorbed by the body.

---

Q: How quickly is the sealing effect of Tachosil supposed to start?

A: The active components coated on the patch are designed to react very rapidly upon contact with physiological fluids. Clinical trials that measured the effectiveness of the patch typically evaluated if hemostasis (stopping the bleeding) was achieved after holding the patch in place for 3 to 5 minutes.

---

Q: What happens to the patch itself over time in the body?

A: The patch is designed to deliver the clotting factors, form a seal, and its components are intended to be absorbed. Both the fibrin seal and the collagen carrier matrix are broken down and eliminated by the body's natural biological processes over time.

---

Q: Are there any long-term concerns for the area where Tachosil was applied?

A: Regulatory documents note that potential long-term risks, such as adhesion formation (scar tissue), are monitored as part of ongoing safety surveillance. Since the patch is designed to be absorbed, the major regulatory focus is on acute safety during the operation.

---

Q: What does the absorbable part of the description mean for patients?

A: The term means that the materials making up the patch and the resulting biological seal are intended to be broken down and eliminated by the body's natural metabolic processes. This means the patch is not intended to remain in place permanently.

---

Q: Is Tachosil approved for use in all types of organ surgeries?

A: No. TachoSil is specifically indicated for use as an adjunct to stop bleeding or seal tissue in certain procedures, such as cardiovascular, hepatic (liver), and neurological surgery. Its official indications focus on use in certain surgical fields, such as cardiovascular, hepatic, and neurological surgery.

---

Q: Is there a chance the Tachosil patch could move after it's applied?

A: Official product information notes the importance of adherence, stating the patch must be held with firm pressure for a period of time to ensure it bonds securely to the tissue. Regulatory warnings exist regarding the risk of the material dislodging if it is not adhered properly.

---

Q: What is the difference between a hemostatic agent and a sealant in this context?

A: The product officially acts as both. It is a hemostatic agent because the clotting factors cause rapid bleeding control (hemostasis). It is also described as a sealant matrix because the resulting fibrin mesh provides a physical obstruction that seals the tissue and prevents leakage.

---

Q: Are there warnings about using Tachosil near large blood vessels?

A: Yes, there is a critical safety restriction. Official prescribing information includes a critical safety restriction that prohibits intravascular application, meaning the patch is not to be applied inside a blood vessel. Applying it internally could lead to life-threatening blood clots (thromboembolic events).

---

Q: Is the safety profile of Tachosil well-established?

A: The safety profile has been established through clinical trials and post-market monitoring. Regulatory documents track known and potential risks like thrombosis (clotting) and allergic reactions. The safety profile has been established through clinical trials and post-market monitoring, though research evidence indicates that long-term follow-up in pivotal studies was limited.

---

Q: What should a patient expect if the doctor says they are using a Tachosil patch?

A: If a doctor indicates TachoSil will be used, the product is applied during the surgical procedure as a supplement to help stop bleeding or seal tissue. It is applied locally to the wound site and is designed to be left in place and absorbed by the body over time.

---

Q: Is Tachosil used in emergency situations?

A: The product is indicated for use as an adjunct during surgery when standard bleeding control techniques are impractical or ineffective. While the main studies were often conducted during planned, elective procedures, the product is used in surgical contexts where immediate bleeding control is necessary.

---

Q: Are there different strengths or sizes of the Tachosil patch?

A: Yes. The patch is supplied in different sizes, such as 9.5 cm imes 4.8 cm and 4.8 cm imes 4.8 cm. These different sizes contain specific amounts of the active clotting components (fibrinogen and thrombin).

---

Q: What is the maximum number of patches that can be used in one surgery?

A: The official prescribing information defines a maximum recommended surface area for use in a single procedure. For example, the FDA documentation specifies limits on the number of patches based on size, such as a maximum of 10 patches of the larger size or 14 patches of the smaller size.

---

Q: Do regulatory agencies classify Tachosil as a drug or a device?

A: TachoSil is generally classified by regulatory agencies as a drug-device combination product. This is because it combines active drug components (fibrinogen and thrombin) coated onto a collagen material, which serves as a medical device matrix.

---

Q: How does Tachosil compare to traditional sutures (stitches)?

A: Official information indicates the patch is intended for use as an adjunct (supplement) to standard surgical techniques when those methods are deemed impractical or ineffective. It is explicitly not intended to be used in place of sutures for controlling major bleeding.

---

Q: Are there any delayed side effects associated with the patch?

A: Official regulatory surveillance tracks all adverse events, including the possibility of delayed effects. Potential events like adhesion formation are monitored as part of the safety profile, but no specific delayed effects are listed in the common or uncommon categories.

---

Q: Does Tachosil affect how long a person needs to stay in the hospital?

A: The product is intended to assist hemostasis and sealing during surgery. While its intended role is to reduce bleeding and complications, regulatory labels make no direct claim about the duration of a patient's stay in the hospital.

---

Q: Is Tachosil a prescription drug?

A: Yes, TachoSil is classified as a prescription-only medicine. Its use is restricted to administration by or under the supervision of a healthcare professional in a surgical setting.

---

Q: Are there any reports of Tachosil causing problems with wound healing?

A: Regulatory documentation includes warnings about the risk of adhesion formation (scar tissue) when the patch is used outside of the intended application area, though problems with general wound healing are not directly reported.

---

Q: Do patients need to fast or change their diet before a procedure involving Tachosil?

A: Since the product is only applied topically to the wound site during surgery, specific pre-administration patient instructions regarding fasting or diet changes related to the patch itself are not included in the regulatory documentation. Standard surgical preparation rules apply independently.

---

Q: What kind of training do surgeons need to use the Tachosil patch?

A: The official prescribing information indicates that the use of TachoSil is restricted to experienced surgeons.

---

Q: Are there any known interactions between Tachosil and general anesthesia?

A: Regulatory documents state that no formal interaction studies have been performed for systemic medicines, and no specific interactions with general anesthesia are documented. This is due to its local, topical application and minimal systemic absorption.

---

Q: Can the patch be cut to size by the surgeon?

A: Yes, the official prescribing information indicates the patch can be cut to the smallest size needed by the surgeon to adequately cover the application area.

---

Q: Are the proteins in Tachosil genetically modified?

A: The active proteins (Fibrinogen and Thrombin) are derived from purified human plasma. The regulatory description does not indicate that these components are genetically modified.

---

Q: Does the application of Tachosil affect the durability of the surgical repair?

A: Official documentation indicates that the patch is used for suture support in procedures like vascular surgery, suggesting its intended role is to enhance the stability and integrity of the surgical repair by providing an immediate, strong biological seal.

---

Q: What steps are taken to ensure the sterility of the Tachosil patch?

A: The patch is supplied as a sterile product. The instructions emphasize that the patch must be handled according to strict protocols after the outer packaging is opened, and it cannot be resterilised.

---

Q: Is there any indication that Tachosil may impact fertility?

A: Official regulatory information does not contain specific warnings about an impact on human fertility. While human safety data for use during pregnancy and lactation is limited, animal studies concerning fertility have been conducted.

How to Store and Dispose of TachoSil

Official regulatory documents define strict conditions for storing TachoSil to maintain its stability. The product must be stored in its unopened original package and protected from light and moisture.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Do not store above 25 °C (77 °F).
Freezing	Do not freeze.
Child Safety	Keep out of the sight and reach of children.

Stability and Disposal

The TachoSil patch must be used immediately after the outer foil sachet has been opened, as the product cannot be re-sterilized or stored. Disposal of any unused TachoSil product or associated waste material must be carried out in accordance with local regulatory requirements.